Optical News

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros...

GENEVA--(BUSINESS WIRE)--Alcon Completes $750 Million Share Repurchase Program...

GENEVA--(BUSINESS WIRE)--Alcon Completes $750 Million Share Repurchase Program...

DUBLIN--(BUSINESS WIRE)--The "Artificial Iris Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Artificial Iris Market has shown significant growth, expanding from USD 17.71 million in 2024 to USD 19.31 million in 2025 and is expected to reach USD 36.92 million by 2032, growing at a CAGR of 9.61%. As biomedical innovation, consumer trends, and regulatory evolution converge, new opportunities in artificial iris technologies are emerging. Artificial iris...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior t...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2025 financial results after the market close on Tuesday, February 17, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17,...

MENLO PARK, Calif.--(BUSINESS WIRE)--Emmecell announces the appointment of ophthalmology leader Ramin Valian as CEO....

CHICAGO--(BUSINESS WIRE)--Chicago Atlantic announced its role as sole arranger and administrative agent in the closing of a $16.5 million senior secured term loan for Ocular Science, Inc. (“Ocular Science”), an affiliate of OSRX, Inc. OSRX is a leading provider of compounded ophthalmic medications. Founded in 2015 and guided by a medical advisory board of 31 world leaders in ophthalmology, Ocular Science focuses on the production of paradigm-shifting therapeutic solutions for eye care that are...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates (“Broadwood”), which together own 31% of STAAR’s outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5% of ST...

ALAMEDA, Calif.--(BUSINESS WIRE)--An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation’s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 million people worldwide. The editorial, Behind the Science: Restoring Vision for Patients with AMD a...